The global CAR T cell therapy market is estimated to grow at a CAGR of nearly 48% during the forecast period. The major factors contributing to the growth of the market include a significant prevalence of cancer across the globe and rising FDA approvals for cell and gene therapy. As per the World Health Organization (WHO), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. There were 43.8 million persons living with cancer in 2018 who were diagnosed within the last 5 years. This rising prevalence of cancer is attributing to the development of CAR T cell therapy. It is a form of immunotherapy that utilizes specially altered T cells, a part of the immune system to attack cancer.
Request a free sample of our report on CAR T Cell Therapy Market: https://www.omrglobal.com/request-sample/car-t-cell-therapy-market
There are currently two CAR T cell therapies approved for the treatment of cancer, which includes Yescarta and Kymriah. Yescarta was approved by the US FDA in October 2017, for the treatment of diffuse large B-cell lymphoma (DLBCL). Kymriah was approved by the US FDA in May 2018, for the treatment of adults with certain kinds of non-Hodgkin lymphoma. Kymriah is also approved for the treatment of children and young adults with leukemia. In clinical trials, more than 80% of young adults and children treated with Kymriah achieved cancer remission.
A full report of CAR T Cell Therapy Market Is available at: https://www.omrglobal.com/industry-reports/car-t-cell-therapy-market
Global CAR T Cell Therapy Market Segmentation
By Application
Non-Hodgkin Lymphoma
Acute Lymphocytic Leukemia
Others (Multiple Myeloma, Hodgkin Lymphoma, and Breast Cancer)
By Target Antigen
CD19
CD22
Others (CD123, CD33, and BCMA)
Regional Analysis
North America
United States
Canada
Europe
UK
Germany
Italy
Spain
France
Rest of Europe
Asia-Pacific
China
India
Japan
Rest of Asia-Pacific
Rest of the World
Company Profiles
Amgen Inc.
Autolus Therapeutics plc
bluebird bio, Inc.
Bristol-Myers Squibb Co.
CARsgen Therapeutics Co., Ltd.
Cellectis SA
Celyad SA
Gilead Sciences, Inc.
Intellia Therapeutics, Inc.
Janssen Global Services, LLC (a Subsidiary of Johnson & Johnson)
For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/car-t-cell-therapy-market
About us:
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting, and other research-based services.
For More Information, Visit https://www.omrglobal.com/
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email:
[email protected]
Contact no: +91 780-304-0404